期刊
ONCOTARGET
卷 5, 期 7, 页码 1701-1752出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.1892
关键词
melanoma; targeted therapy; immune therapy
资金
- NCI NIH HHS [P01 CA163222] Funding Source: Medline
- NIAMS NIH HHS [R01 AR043369] Funding Source: Medline
This review aims to summarize the current knowledge of molecular pathways and their clinical relevance in melanoma. Metastatic melanoma was a grim diagnosis, but in recent years tremendous advances have been made in treatments. Chemotherapy provided little benefit in these patients, but development of targeted and new immune approaches made radical changes in prognosis. This would not have happened without remarkable advances in understanding the biology of disease and tremendous progress in the genomic (and other omics) scale analyses of tumors. The big problems facing the field are no longer focused exclusively on the development of new treatment modalities, though this is a very busy area of clinical research. The focus shifted now to understanding and overcoming resistance to targeted therapies, and understanding the underlying causes of the heterogeneous responses to immune therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据